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Causal Comparisons in Randomized Trials of
Two Active Treatments: The Effect of
Supervised Exercise to Promote Smoking
Cessation
Jason Roy and Joseph W. Hogan

Abstract

In behavioral medicine trials, such as smoking cessation trials, two or more active treatments are often compared. Noncompliance by some subjects with their
assigned treatment poses a challenge to the data analyst. Causal parameters of
interest might include those defined by subpopulations based on their potential
compliance status under each assignment, using the principal stratification framework (e.g., causal effect of new therapy compared to standard therapy among subjects that would comply with either intervention). Even if subjects in one arm do
not have access to the other treatment(s), the causal effect of each treatment typically can only be identified from the outcome, randomization and compliance data
within certain bounds. We propose to use additional information – compliancepredictive covariates – to help identify the causal effects. Our approach is to
specify marginal compliance models conditional on covariates within each arm
of the study. Parameters from these models can be identified from the data. We
then link the two compliance models through an association model that depends
on a parameter that is not identifiable, but has a meaningful interpretation; this
parameter forms the basis for a sensitivity analysis. We demonstrate the benefit
of utilizing covariate information in both a simulation study and in an analysis of
data from a smoking cessation trial.

Causal comparisons in randomized trials of two active treatments:
The effect of supervised exercise to promote smoking cessation

Summary. In behavioral medicine trials, such as smoking cessation trials, two or more active
treatments are often compared. Noncompliance by some subjects with their assigned treatment
poses a challenge to the data analyst. Causal parameters of interest might include those defined
by subpopulations based on their potential compliance status under each assignment, using the
principal stratification framework (e.g., causal effect of new therapy compared to standard therapy
among subjects that would comply with either intervention). Even if subjects in one arm do
not have access to the other treatment(s), the causal effect of each treatment typically can only
be identified from the outcome, randomization and compliance data within certain bounds. We
propose to use additional information – compliance-predictive covariates – to help identify the
causal effects. Our approach is to specify marginal compliance models conditional on covariates
within each arm of the study. Parameters from these models can be identified from the data. We
then link the two compliance models through an association model that depends on a parameter
that is not identifiable, but has a meaningful interpretation; this parameter forms the basis for
a sensitivity analysis. We demonstrate the benefit of utilizing covariate information in both a
simulation study and in an analysis of data from a smoking cessation trial.
Key Words: Bounds; Causal effect; Latent class model; Noncompliance; Principal stratification;
Potential outcomes; Randomized trial.
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1

Introduction

In many clinical trials, the objective is to compare a new treatment to placebo or no treatment.
In trials of new behavioral interventions, however, the experimental design frequently calls for
comparing a new or improved intervention with the current standard of care – an ‘active’ treatment
– rather than a placebo. For example, in trials of interventions designed to promote behaviors such
as smoking cessation, weight loss, or improved adherence to medication, new interventions typically
are compared to a standard of care such as cognitive behavioral therapy.
In a trial of active treatment versus placebo, interest typically focuses on the effect of the
treatment relative to no treatment. Causal comparisons might be defined in terms of outcome
under full compliance with treatment versus no compliance with treatment. For trials with two
active treatments, however, it is possible to contemplate more than one treatment effect, such
as new treatment versus standard of care, new treatment versus no treatment, or new treatment
versus not having new treatment (in this last case, ‘not having new treatment’ may be defined as
any treatment not involving the new one).
A key complication in drawing inference about causal effects in any trial is that compliance is
rarely perfect. In trials of an active treatment versus placebo, it is possible to recover causal effects
under some reasonably mild assumptions. For all-or-none compliance situations (i.e., compliance is
a binary variable), the method of instrumental variables can be particularly useful (Angrist, Imbens
and Rubin, 1996). Causal effects among compliers (subjects that would take treatment if offered)
are identifiable if there are no defiers (subject who would take the active treatment in the control
arm but not in the treatment arm). This assumption is particularly reasonable in placebo controlled
trials, or in trials where the control group does not have access to the active treatment. In such
settings, the instrumental variables estimator is equivalent to the estimator from certain structural
mean models (Robins 1994; Goetghebeur and Lapp 1997; Robins and Rotnitzky 2004). Structural
mean models can also be used when compliance is continuous, and if there are interactions between
the causal effect and baseline covariates. However, if it is unreasonable to assume there are no
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defiers, the causal parameters are generally not identifiable without structural assumptions; several
authors have derived bounds on the causal effects (Robins 1989; Balke and Pearl 1997; Joffe 2001).
In other settings, particularly when a standard of care exists and must be included for comparison, the trial will compare two or more active treatments. For example, in trials of new antiviral
therapy regimens for those with HIV infection, comparison with a placebo is typically not ethically
viable. Trials of behavioral interventions, where new interventions are usually tested relative to
a standard or existing behavioral or pharmacologic therapy, also are representative. A specific
example is the Commit to Quit trials (Marcus et al. 1999), comprising two longitudinal follow up
studies of supervised exercise to promote smoking cessation. Each study had two treatment arms.
All participants received cognitive-behavioral smoking cessation therapy (CBT). For those in the
intervention arm, CBT was augmented by an individualized, supervised exercise program. In order
to equalize increased contact hours between the two arms, CBT for those in the control arm was
augmented by a wellness education program that included lectures, films, handouts and discussions
covering issues such as healthy eating and prevention of cardiovascular disease. Hence the comparison is between standard therapy augmented by ‘wellness’ and standard therapy augmented by an
exercise regimen. Another particularly useful feature of behavioral intervention trials for drawing
causal inferences is that compliance is fully observed when the intervention comes in the form of
group therapy or other supervised activity.
A useful framework for drawing causal inference about the effect of a post-randomization outcome such as compliance with treatment is principal stratification (Frangakis and Rubin 2002).
Causal effects are characterized within subpopulations, or principal strata, defined by potential
values of a post-treatment stratification variable. When compliance is the post-treatment variable,
principal stratification can be used to identify causal contrasts associated with receiving treatments
under study. For example, in a trial where individuals are randomized to one of two active treatments, say A and B, and where compliance is a binary post-treatment variable (1 = yes, 0 = no),
there are four principal strata defined by the pairs of potential values of compliance, those who

2
Hosted by The Berkeley Electronic Press

would: (i) comply with both A and B, (ii) comply with A but not B, (iii) comply with B but not
A, and (iv) comply with neither.
The causal effect of being randomized to one treatment arm versus another is the intention to
treat (ITT) effect. It is estimable for a population and, by virtue of randomization, the estimate
captures a causal effect (here, the causal effect of being randomized to A versus B, averaged over
post-stratification variables). Causal effects of receiving treatment can be defined as (or in terms of)
ITT contrasts within each principal stratum. For example, the causal effect of receiving A versus
B is the effect of being randomized to A versus B among those who would comply with either; i.e.
among those in stratum (i).
The ITT effect within other strata are still causal effects, but may not be of direct interest.
For example, the ITT effect among those in stratum (ii) — comprising subjects who would comply
with treatment A but not treatment B — gives the causal effect of receiving treatment A relative
to receiving neither A nor B.
Although the principal stratification approach is useful for defining the causal parameters of
interest, there is still an identifiability problem. In the absence of covariates, one can derive bounds
on causal contrasts associated with receiving one treatment relative to another. Cheng and Small
(2006) derived bounds on the distribution of principal strata and causal effects for trials with two
active treatments and non-compliance; how tight the bounds are depends on the assumptions one
is willing to make.
The goal of our approach is to identify causal parameters of interest by utilizing information
from baseline covariates that are predictive of compliance. Each individual has two potential values
of the post-randomization variable, say A0 and A1 , where Az is the indicator that the subject would
comply with treatment z for z = 0, 1; only one is observed. Our approach relies on a model for the
joint distribution of (A0 , A1) as a function of baseline covariates X. The joint distribution is written
in terms of the treatment-arm-specific means, together with an association model; the association is
parameterized so as not to affect the marginal distributions and to ensure that the joint probabilities
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stay within the appropriate bounds. Using the model for [A0, A1 | X], and assuming it is correctly
specified, we are able to identify probability of membership in each principal stratum up to a
sensitivity parameter that characterizes within-subject association between compliance with each
of the active treatments; e.g. conditional on baseline covariates, the probability that an individual
would comply with treatment A, given compliance status for treatment B. We can then identify
the causal parameters at each fixed value of the sensitivity parameter.
In Section 2 we describe the smoking cessation trial. We introduce the notation, assumptions
and bounds on the causal effects in Section 3. In Section 4 we present the compliance models. The
likelihood, prior and posterior distributions are described in Section 5. Section 6 describes a brief
simulation study. Data from the CTQ smoking cessation trial are analyzed in Section 7. Finally,
there are concluding remarks in Section 8.

2

Data from ‘Commit to Quit’ trial

The Commit to Quit study (Marcus et al., 1999) is a randomized controlled trial designed to assess the efficacy of supervised vigorous exercise as an adjuvant to cognitive behavioral therapy to
promote smoking cessation among women. A primary motivation behind studying women exclusively is that in the mid-1990’s, smoking prevalence rates among women were declining at a slower
rate than among men (Escobedo and Peddicord 1996). The study enrolled and randomized 281
women to receive CBT plus vigorous exercise (the new treatment) or CBT plus a wellness education program (the control treatment). CBT represents the standard of care for smoking cessation;
the wellness education was added to the control arm to equalize staff contact time between the
two arms and to eliminate the possibility that treatment effects associated with exercising might
be confounded by added staff time. The CBT program was administered to all women in group
format weekly over the course of 12 weeks. The exercise program was individually tailored to each
woman based on achieving a target heart rate; women exercised three times weekly, and each session was supervised by an exercise specialist. Women in the control arm participated in a program
of supervised lectures, films and discussions three times weekly, and were instructed not to adopt a
4
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program of regular exercise until the study was completed. None of the women in the control arm
had access to the supervised exercise program.
Smoking status was evaluated weekly over the course of 12 weeks. The target quit date was week
5 following randomization. Weekly quit status was assessed by self report and verified by carbon
monoxide (<8ppm) and saliva cotinine (<10 ng/mL). To be considered abstinent, an individual
needed to submit to testing and meet both the carbon monoxide and saliva cotinine criteria. The
primary outcome of the study, and the one we consider here, was continuous abstinence during the
8 weeks after the quit date. Consistent with the criteria used in Marcus et al. (1999), an individual
who was not present for scheduled testing for one or more occasions during the study could not be
counted as continuously abstinent.
Subjects were expected to attend 3 wellness or exercise classes per week. We defined compliance
based on the number of sessions actually attended during the first 4 weeks of the trial (i.e., during
the weeks prior to the quit date). Specifically, we defined a subject as compliant with their assigned
treatment if they attended two-thirds of the classes every week and attended all 3 classes at least 2
of the weeks, during weeks 1 to 4. For clarity, this is depicted in Figure 1. Compliance status was
observed for all subjects (no missing data).
Figure 1: Commit to Quit trial
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A total of 147 and 134 subjects were randomized to the wellness and exercise arms, respectively.
Compliance was similar in the wellness and exercise arms (41% and 43%, respectively). A total of
10.8% of subjects in the wellness arm were continually abstinent during the 8 weeks after the quit
date, compared to 19.4% in the exercise arm.
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3

Principal stratification with two active treatments

3.1

Notation and assumptions

We consider experimental trials with two arms – each with an active treatment. Our approach
could easily be extended to three arm trials with two active treatments (where one arm is a control
group), such as considered by Cheng and Small (2006). Let Zi ∈ {0, 1} denote randomization
indicator for subject i (i = 1, · · · , n), where Zi = 1 indicates randomization to the new treatment
(e.g., supervised exercise plus CBT), and Zi = 0 indicates randomization to standard therapy (e.g.,
wellness sessions plus CBT). For each individual, let Az ∈ {0, 1} denote compliance with assigned
treatment under treatment assignment z. Therefore, each person has two potential treatments A0
and A1 that characterize their compliance behavior under either treatment assignment; however
only A = ZA1 + (1 − Z)A0 is observed. Similarly, each subject also has two potential outcomes,
Y0 and Y1 , but only one is observed; we denote this as Y = ZY1 + (1 − Z)Y0 . We next describe
several key assumptions that we will rely on in the development of analytic methods.
Assumption 1. Stable Unit Treatment Value Assumption (SUTVA) (Angrist, Imbens and Rubin
1996). The potential compliance values of a subject do not depend on the treatment assignment
of other subjects. In addition, the potential outcomes for a given subject do not depend on the
assigned treatments or compliance status of other subjects.
Assumption 2. Randomization. We assume treatment is randomly assigned, which implies
Z⊥
⊥ {Y0, Y1 , A0, A1}.
Assumption 3. Exclusion restriction. Treatment assignment Z only affects the outcome through
its effect on treatment received.
Assumptions 1-3 imply that Z is an instrumental variable.
Assumption 4. Treatment access restriction. Subjects in group Z = z do not have access to the
active treatment assigned in arm Z = 1 − z, for z = 0, 1. In the CTQ study, this assumption holds
because subjects in the wellness arm were not allowed to attend the exercise classes, while subjects
in the exercise arm were not allowed to attend the wellness classes.
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Assumption 5. Monotonicity. Compared with the general population, the subpopulation who
would comply with active control (Z = 0) are at least as likely to comply with the new intervention
(Z = 1); i.e., P (A1 = 1|A0 = 1) ≥ P (A1 = 1).

3.2

Defining causal effects

We assume each individual belongs to one of four basic principal strata (Frangakis and Rubin 2002)
defined by unique combinations of (A0 , A1). In our case, these are {(0, 0), (0, 1), (1, 0), (1, 1)}; the
random variable S ∈ {0, 1, 2, 3} denotes stratum membership. Hence the subpopulation with S = 3
characterizes those individuals who would comply with whichever treatment was offered; those with
S = 2 would comply with the new treatment, but not the standard treatment; those with S = 1
would comply with standard treatment, but not the new treatment; and finally those with S = 0
would not comply with either intervention.
We are now ready to define causal contrasts of interest. In the most general terms, we are seeking
the joint distribution [(Y0, Y1 ) | S = s], which characterizes the causal effect of randomization to
treatment within the subpopulation comprising principal stratum s. For example, the distribution
[(Y0, Y1 ) | S = 3] captures causal effect new therapy relative to standard therapy, among the
subpopulation that would comply with either intervention.
Let πz (s) = P (Yz = 1|S = s). One potential parameter of of interest is π1(3) − π0(3), the causal
risk difference among compliers. An odds ratio or risk ratio also could be used. In our analysis of
the CTQ trial, we will use the risk difference π1 (3) − π0 (3) as our primary target for inference. We
also will consider risk differences derived from [(Y0, Y1) | S ∈ {2, 3}], which captures the effect of
new treatment among subjects that would comply with new treatment; and from [(Y0, Y1) | S = 2],
which characterizes the effect of new therapy relative to no intervention among the subpopulation
of subjects that would comply with the new therapy but not standard treatment.
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3.3

Bounds on causal effects in the absence of covariates

In trials with 2 active treatments, the causal effects within each basic principal stratum are not
point identified from the outcome and compliance data alone under assumptions 1-4 (Cheng and
Small 2006). However, one can derive bounds for the strata probabilities and the causal effects.
First, consider bounds on the distribution of S. Using assumptions 1-4, Cheng and Small (2006)
derived bounds for P (S = s), s = 0, 1, 2, 3. They also derived bounds based on a fifth assumption,
that P (A1 = 1|A0 = 1) = 1. That assumption is not realistic for the CTQ study, as it is not hard
to imagine that there are subjects who would comply with exercise but not wellness, or vice versa.
We instead make a weaker fifth assumption, that P (A1 = 1|A0 = 1) ≥ P (A1 = 1). The bounds
on the distribution of S based on our assumptions 1-5 are as follows. Let ψ0 = P (A0 = 1) and
ψ1 = P (A1 = 1). The bounds are then
(1 − ψ1)(1 − ψ0) ≤ P (S = 0) ≤ min(1 − ψ0 , 1 − ψ1)
max(0, ψ0 − ψ1) ≤ P (S = 1) ≤ ψ0(1 − ψ1)
max(0, ψ1 − ψ0) ≤ P (S = 2) ≤ ψ1(1 − ψ0)
ψ0 ψ1 ≤ P (S = 3) ≤ min(ψ0, ψ1).
We next consider bounds on the causal effects. We focus here on the average causal effect of new
treatment compared to standard treatment, among those subjects that would comply with either
intervention, i.e., π1 (3) − π0 (3). Let P (S = 3) = p3 and I = [ψ0ψ1, min(ψ0, ψ1)], then, as derived
in Cheng and Small (2006), the lower bound of π1 (3) − π0 (3) is




1 − P (Y = 1|Z = 1, A = 1)
min max 0, 1 −
p3 ∈I
p3 /P (A = 1|Z = 1)





P (Y = 1|Z = 0, A = 1)
− min 1,
p3/P (A = 1|Z = 0)



and the upper bound is





P (Y = 1|Z = 1, A = 1)
1 − P (Y = 1|Z = 0, A = 1)
max min 1,
− max 0, 1 −
.
p3 ∈I
p3/P (A = 1|Z = 1)
p3 /P (A = 1|Z = 0)
These bounds can be estimated, as P (Y |Z, A) and P (A|Z) involve only the observed data.
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Our strategy, however, is to identify the causal effects by utilizing information from baseline
covariates that are predictive of compliance. As a hypothetical example, suppose women with a
low body mass index (BMI) were more likely to comply with the wellness intervention than were
women with a high BMI (we could know that by using data from the Z = 0 arm). It is logical
to believe that a woman with low BMI in arm Z = 1 who complied with exercise is more likely
to be in stratum S = 3 than a woman who with high BMI who complied with exercise in arm
Z = 1. That is the kind of information we plan to utilize to identify the causal effects. In the
next section, we describe our strategy for modeling the joint distribution of (A0 , A1) conditional
on baseline covariates.

4

Utilization of compliance-predictive covariates

Assume for each subject we have several baseline covariates X that are associated with compliance
in one or both arms. Our objective is to use the covariate information to model [A0 , A1|X]; however,
only one of A0 and A1 are observed for each subject. Therefore we are able (using randomization
of Z) to identify the marginals [A0 |X] and [A1 |X], we cannot identify the conditional association
between A0 and A1 given X. Our approach is to separately specify the marginal distributions
[A0|X] and [A1 |X], and to use a single nonidentifiable parameter φ to capture the association
structure. This parameter will be used as part of a sensitivity analysis. This idea of specifying the
two marginal distributions separately from the association model is related to work by Heagerty
(2002), except here the association parameter is not identifiable.

4.1

Marginal compliance models

We first modify two of the assumptions from Section 3.1 to take covariate information into account.
The randomization assumption now can be written as Z ⊥
⊥ {Y0 , Y1, A0, A1, X}. That is, we assume
that the assignment mechanism is independent of potential outcomes, potential compliance status,
and baseline covariates. We also assume that assumption 5 holds within levels of the covariates,
i.e., P (A1 = 1|A0 = 1, X = x) ≥ P (A1 = 1|X = x), for all x.
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We next specify models for the marginal means of the potential compliance outcomes. Denote
by X0 ⊆ X the covariates that are predictive of compliance in arm Z = 0 (i.e., [A0 |X] = [A0|X0]),
and by X1 ⊆ X the covariates that are predictive of compliance in arm Z = 1. We would like to
estimate these marginal distributions, but for identifiability, will typically need to define models
for them. Specifically, we assume,

ψ0 (X0) = P (A0 = 1|X0) = m0(X0; λ0)

(1)

ψ1(X1 ) = P (A1 = 1|X1) = m1 (X1; λ1),

(2)

and

where mz (Xz , λz ) are user-specified functions indexed by a finite-dimensional parameter λz , z =
0, 1. For example, one could specify logistic regression models ψ0(X0) = logit−1 (X0T λ0 ) and
ψ1(X1) = logit−1 (X1T λ1). Recall that A = ZA1 + (1 − Z)A0 is the observed compliance variable. By Assumption 2 (randomization), [A0|X] = [A|X, Z = 0] and [A1|X] = [A|X, Z = 1].
Therefore, the λ parameters, and hence the marginal probabilities ψ0(X0) and ψ1 (X1), are identifiable from the observed data. The usual diagnostic methods can be used to check the adequacy of
the mz (·; ·).

4.2

Association model

To complete specification of the joint distribution [A0, A1|X], we need to link the two marginal
distributions together. Our goal is to specify a model for the association between A0 and A1 given
X, that satisfies the following:
1. The association can be characterized by a single parameter φ, which cannot generally be
identified from the compliance data and covariates.
2. Any value of φ in the specified range should yield a model for [A0, A1|X] that is fully compatible with the assumed marginal distributions (1) and (2).
10
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3. Any value of φ in the specified range should lead to valid conditional probabilities (e.g.,
P (A1 |A0, x) must be between 0 and 1).
Our association model must account for the fact that the marginal models (1) and (2) imply
restrictions on the range of possible probabilities in the conditional models P (A1 |A0, X). Given
assumptions 1-5 and marginal models (1) and (2), the joint distribution P (A0 = 1, A1 = 1|X = x)
is bounded by ψ0 (x)ψ1(x) ≤ P (A0 = 1, A1 = 1|X = x) ≤ min{ψ0(x), ψ1(x)}. This implies the
following bounds on the conditional distribution



ψ1(x)
ψ1(x) ≤ P (A1 = 1|A0 = 1, X = x) ≤ min 1,
.
ψ0(x)
n
o
1 (x)
Denote the upper bound by ∆U (x) = min 1, ψ
. We propose the following model:
ψ0 (x)
P (A1 = 1|A0 = 1, X = x) = ψ1(x) + φ{∆U (x) − ψ1 (x)}, 0 ≤ φ ≤ 1.

(3)

Interpretation of φ. If φ = 0, then P (A1 = 1|A0 = 1, X = x) = ψ1(x), for all x, which
is the conditional independence assumption (i.e. A1 independent from A0 given X). If φ = 1,
then P (A1 = 1|A0 = 1, x) = ∆U (x), which is the largest possible probability that is compatible
with the marginal distributions. For example, if more people with covariates x would comply with
the new treatment than the standard treatment (i.e., ψ1 (x) > ψ0(x)), then setting φ = 1 would
be making the assumption that everyone with covariates x that would comply with the standard
treatment would also comply with the new treatment. If compliance with the new treatment is
less likely than compliance with the standard treatment, among those that have covariates x, then
setting φ = 1 implies that ψ1(x)/ψ0(x) × 100 percent of the subjects that would comply with
the standard treatment would also comply with the new treatment. As an extreme example, if
ψ1(x) = 0, then no one with covariates x would comply with the new treatment, and therefore
P (A1 = 1|A0 = 1, X = x) = 0.
The marginal distributions (1) and (2) and conditional probability (3) imply a model for P (A1 =
1|A0 = 0, X = x). Specifically, the probability P (A1 = 1|X = x) can be written as
P (A1 = 1|X = x) =

1
X

P (A1 = 1|A0 = a, X = x)P (A0 = a|X = x),

a=0
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which implies
ψ1 (x) = [ψ1(x) + φ{∆U (x) − ψ1 (x)}]ψ0(x) + P (A1 = 1|A0 = 0, x){1 − ψ0(x)}.
Solving the above equation for P (A1 = 1|A0 = 0, X = x) results in
P (A1 = 1|A0 = 0, X = x) =

ψ1(x) − [ψ1(x) + φ{∆U (x) − ψ1(x)}]ψ0(x)
.
1 − ψ0(x)

Our assumed association model is therefore
P (A1 = 1|A0 = a, X = x) = a[ψ1(x) + φ{∆U (x) − ψ1(x)}]
+ (1 − a)

ψ1(x) − [ψ1(x) + φ{∆U (x) − ψ1(x)}]ψ0(x)
1 − ψ0 (x)

(4)

This specification ensures that conditions 1 – 3 are met.

5

Inference methods

Inferences are based on an observed-data posterior distribution. We begin by writing a full-data
likelihood for the joint distribution of all potential outcomes and covariates, [Y0 , Y1, A0, A1, X, Z].
Priors are placed on the full-data parameters. The observed-data posterior is obtained by integrating the full-data model over the distribution of missing outcomes.

5.1

Full data likelihood

The main strategy pursued here is to specify the full-data model, and then impose necessary assumptions for identifying parameters of interest. Let β = (φ, λ1, λ0) and let θ denote the collection
of parameters that characterize [(Y0, Y1 ) | S]. We denote the full-data joint distribution generically as [Y0 , Y1, A0, A1, Z, X] (equivalently [Y0 , Y1, S, Z, X]), and decompose it using the following
factorization (where f (· | ·) denotes a model for conditional distribution),
f (Y0 , Y1, A0, A1, Z, X | θ, β, ξ) = f (Y0 , Y1 | S, Z, X, θ) × f (A0 , A1 | Z, X, β) × f (X, Z | ξ).

(5)

The variable S appears in the first factor because conditioning on (A0, A1) is equivalent to conditioning on S. The full-data likelihood contribution for a single individual is any function proportional
12
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in (θ, β, ξ) to the joint distribution (5), evaluated at Fi = (Y0i , Y1i , A0i, A1i, Zi, Xi). The full-data
Q
likelihood is denoted generically by L(θ, β, ξ | F ) = ni=1 L(θ, β, ξ | Fi ).
Because it is not possible to observe the full data, inference must be based on an observed-data
posterior distribution. The likelihood part of the observed-data posterior is derived by integrating
missing observations out of the joint distribution (5). Before proceeding, we make two assumptions
about the full-data likelihood. First, we assume the potential outcomes are jointly independent of
Z and X within principal stratum, so that
f (Y0 , Y1 | S, Z, X, θ) = f (Y0 , Y1 | S, θ).

(6)

This implies the causal effects within strata are independent of both Z and X. For discrete X,
this assumption can be relaxed to the extent that this methodology can be applied separately at
distinct levels of X. Second, we assume the potential outcomes related to compliance are jointly
independent of Z, conditionally on X,
f (A0, A1 | Z, X, β) = f (A0 , A1 | X, β).

(7)

Because A0 and A1 jointly determine S, this assumption means that conditionally on X, membership in principal stratum S is independent of treatment assignment Z (randomization assumption).
To parameterize the joint distribution of potential responses in (6), observe that there are four
possible realizations of (Y0, Y1 ) at each level of S. Therefore f1 (Y0 , Y1 | S, θ) can be parameterized in
P
P
terms of the probabilities θy0 y1 (s) = pr(Y0 = y0 , Y1 = y1 | S = s), where 1y0 =0 1y1 =0 θy0 y1 (s) = 1
for any s. The distribution is represented on Table 1. Notice that θ10 (0) = θ01 (0) = 0 because
under no exposure to any intervention, the potential outcomes cannot differ (exclusion restriction).
Hence
f (Y0 , Y1 | S, θ) =

n

θ00(0)(1−Y1 )(1−Y0 ) θ11(0)Y1 Y0

×

3 n
Y

oI(S=0)

θ00 (s)(1−Y1 )(1−Y0 ) θ01(s)(1−Y0 )Y1 θ10(s)Y0 (1−Y1 ) θ11 (s)Y0 Y1

oI(S=s)

.

s=1

The model for potential compliance variables given in (7) is specified using the factorization
f (A0 , A1 | X) = f (A0 | X) f (A1 | A0 , X), where, from (1), the first factor is the Bernoulli mass
13
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Table 1: Parameters indexing the joint distribution of potential outcomes within each principal
stratum, [Y0, Y1 | S]. Each row of probabilities sums to one.

A0
0
1
0
1

A1
0
0
1
1

S
0
1
2
3

(0,0)
θ00 (0)
θ00 (1)
θ00 (2)
θ00 (3)

(Y0 , Y1)
(0,1)
(1,0)
0
0
θ01 (1) θ10(1)
θ01 (2) θ10(2)
θ01 (3) θ10(3)

(1,1)
θ11 (0)
θ11 (1)
θ11 (2)
θ11 (3)

function f (A0 | X) = ψ0(X)A0 {1−ψ0 (X)}1−A0 . The second factor also is Bernoulli with probability
given by (3).
To round out the model specification, we assume the parameters (θ, β) are a-priori jointly
independent of ξ; i.e., p(θ, β, ξ) = p(θ, β) p(ξ). A consequence of this is that the full-data posterior
factors over (θ, β) and ξ,
p(θ, β, ξ | F ) ∝

(

p(θ, β)

×

(

p(ξ)

n
Y
i=1
n
Y

f (Y0i , Y1i | Si , θ) f (A0i | Xi , β)f (A1i | A0i, Xi, β)

)

)

f (Xi , Zi | ξ)

i=1

= p(θ, β | F ) p(ξ | F ).
We will see momentarily that the observed-data posterior also factors over (β, θ) and ξ, obviating
the need to specify f (X, Z | ξ) and p(ξ).

5.2

Observed-data likelihood and posterior

The observed data likelihood is obtained by integrating over the sample space of missing potential outcomes. For those randomized to treatment group Z, the pair (YZ , AZ ) is observed and
(Y1−Z , A1−Z ) is missing. Equivalently, we can say that {YZ , S(Z, AZ )} is observed, where S(Z, AZ )
is the subset of principal strata compatible with the value of AZ . For example, if Z = 0 and
AZ = A0 = 0, then (A0, A1) ∈ {(0, 0), (0, 1)}, or equivalently S ∈ {0, 2} (see Table 1). Hence
S(0, 0) = {0, 2}.
For an individual on which (YZ , AZ , X) is observed, the contribution to the observed-data
14
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likelihood is proportional in the model parameters to
f (YZ , AZ , Z, X | θ, β, ξ) = f (X, Z | ξ)

ZZ

f (Y0 , Y1 | A0 , A1, θ) f (A0 , A1 | X, β) dY1−Z dA1−Z

X

= f (X, Z | ξ)

1
X

f (YZ , Y1−Z = y | S = s, θ) P (S = s | X, β)

s∈S(Z,AZ ) y=0

(8)
Hence the observed-data likelihood contribution for inference about (θ, β) is simply the double
sum in (8), denoted from here by Lobs(θ, β | YZ , AZ , Z, X). If p(θ, β, ξ) = p(θ, β)p(ξ), then the
observed-data posterior also factors over (θ, β) and ξ, and neither f (X, Z | ξ) nor p(ξ) needs to be
specified to draw inference about the causal parameters θ.
The observed-data likelihood can be simplified and written in terms of the observed outcome
and compliance variables Y and A by considering each (Z, A) combination. For example, if Z = 0
and A = 0, then A0 = 0, S(0, 0) = {0, 2}, and
1
X X

Lobs(θ, β | Y, A = 0, Z = 0, X) =

f (Y0 , Y1 = y | S = s) P (S = s | X)

s∈{0,2} y=0

X 

θ00(s)1−Y θ10 (s)Y + θ01(s)1−Y θ11 (s)Y P (S = s | X).

=

s∈{0,2}

A reparameterization leads to further simplification. For example, notice that π0 (s) = θ10 (s)+θ11(s)
and 1 − π0(s) = θ00(s) + θ01 (s), for s ∈ {0, 2}. Then
Lobs(π, β | Y, A = 0, Z = 0, X) =

X h

i
π0 (s)Y {1 − π0(s)}(1−Y ) P (S = s | X).

s∈{0,2}

If we take a similar approach for the other (Z, A) combinations, it is straightforward to show that
L(π, β | Y, A, Z, X) =

3
X

πZ (s)Y {1 − πZ (s)}1−Y P (S = s | X, β) G(s, A, Z),

s=0

where
G(s, A, Z) = I(s = 0)(1 − A) + I(s = 1){A(1 − Z) + (1 − A)Z}
+ I(s = 2){AZ + (1 − A)(1 − Z)} + I(s = 3)AZ.
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Recall that P (S = s | X, β) is parameterized in terms of λ and φ. The observed data likelihood
is therefore a function (λ0, λ1, φ) and the 7 parameters captured by π (note that π0 (0) = π1 (0) by
exclusion restriction).
In our simulation and data analysis, we used WinBUGS to obtain draws from the observed-data
posterior. Specifics about priors are given in Sections 6 and 7.

6

Simulation study

We carried out a simulation study to assess the performance of the proposed model in finite samples,
and to quantify the benefit of using compliance-predictive covariates. We first simulated group
membership Zi from a Bernoulli distribution with probability 0.5. We generated one covariate:
X1i ∼ N (0, 1) for i = 1, · · · , n. The compliance indicators were generated as follows. First, A0
for subject i was generated from a Bernoulli with probability logit−1(0.4 + cX1i/4). The marginal
distribution of A1 was Bernoulli with probability logit −1 (0.3 + cX1i/2); we considered c = 1 and
c = 2. The model with c = 2 implies a stronger relationship between the covariate in compliance
in both arms. With either model, overall compliance was about 60% in each arm on average. The
variable A1 was generated from the conditional distribution of [A1|A0 , X1; φ], given in (4). The
observed response variable, given S = s and Z = z, was set equal to 1 with probability πz (s),
where π0 (0) = π1 (0) = 0.1, π0 (1) = 0.4, π1(1) = 0.2, π0 (2) = 0.2, π1 (2) = 0.4, π0(3) = 0.4 and
π1 (3) = 0.6. We used n = 250 and generated data for φ = 0.1 and φ = 0.9.
We compared three different model specifications. For each fitted model, we used a burn-in of
500, and ran an additional 2000 draws, on 2 parallel chains. The first used the class membership
S as if it were observed (Model 1). In practice S cannot be observed; however Model 1 is a useful
reference for evaluating the performance of the proposed models. We assumed Y given S and Z
was Bernoulli with probability πz (s), for z = 0, 1, s = 0, 1, 2, 3 and π0(0) = π1 (0), and used Uniform
(0, 1) priors for the π’s.
Next, we fitted two different models to the observed data, using the model given in Section 4
and inference methods described in Section 5. The first of these two did not use the covariate (X1)
16
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in the compliance models (Model 2). That is, P (A0 = 1) = ψ0 and P (A1 = 1) = ψ1 . The values
of λ and φ that were used in generating the data imply a corresponding value of the association
parameter, denoted by φ∗ , in the model without covariates; it satisfied the identity
∗

ψ1 + φ (∆U − ψ1) =
where ψz =

R

Z

[ψ1(x) + φ{∆U (x) − ψ1(x)}] dF (x),

ψz (x)dF (x), z = 0, 1, and ∆U =min(1, ψ1/ψ0). The identity can easily be solved

for φ∗ by approximating the integrals using a Gaussian quadrature. We fitted the model to the
data using the φ∗ that was implied by each set of λ and φ, so that each model could be viewed as
correctly specified.
The next model we fitted included X1 as a predictor of compliance, namely P (A0 = 1) =
logit −1 (λ00 + λ01X1 ) and P (A1 = 1) = logit −1 (λ10 + λ11X1) (Model 3). In each case, we assumed
the conditional distribution of [A1 |A0] followed (4), and that the true value of φ was known. In
each model, relatively flat priors were used for each λ (normal with mean 0 and variance 1000).
Under each scenario, 1000 data sets were generated and analyzed. The data were generated in
R and draws from the posterior were obtained by calling OpenBUGS from R using the package
BRugs. We then examined the frequentist properties of these Bayesian estimators of π1(3) − π0(3),
causal effect of the experimental treatment versus the active control among those who would comply
with either. The posterior medians, width of the 90% credible intervals and whether or not the
interval included the true value were recorded. These were summarized in Table 2 as the average
posterior median across the 1000 samples (median), the standard deviation of these posterior means
(ESD), the proportion of intervals that included the true value of the parameter (coverage) and the
average width of the intervals (width).
Results. For φ = 0.9, models 2 and 3 had a fairly similar performance. The posterior median
of π1 (3) − π0(3) was close to its true value, and ESDs were about 0.09. The credible intervals were
a little wider in the model without covariates, particularly when covariates were strongly predictive
of compliance (c = 2). For both models 2 and 3, the credible interval coverage rates were greater
than their nominal levels (93-97 percent coverage instead of 90 percent coverage), but were closer
17
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to the nominal level for model 3. This suggests that for values of φ close to 1, including covariates
in the model yields relatively modest benefits. For φ equal to 0.1, we found a stronger benefit
from including covariates. Models 2 and 3 both produced posterior medians that were slightly
below the true value of the parameter, on average. Both models were conservative in terms of
coverage probability, but the model that included covariates had better coverage (closer to nominal
level). The width of the interval was substantially smaller for the model that included covariates,
especially when the relationship between the covariate and compliance was strong (a 32% reduction
when c = 2). In general, we see that when φ is near 0, including a covariate in the model that is
predictive of compliance reduces the width of the credible intervals. It is worth bearing in mind
that φ captures association between A0 and A1 conditional on covariates that are prognostic of
compliance; therefore in many applications we can expect that φ is bounded away from 1.

7
7.1

Analysis of commit to quit data
Data

The CTQ study was described in Section 2. The outcome was defined as continuous abstinence
during the course of the trial, a common endpoint in smoking cessation trials. We defined someone
as compliant with their assigned intervention during the 4 weeks prior to the quit date if they
attended at least 2 of the 3 required sessions every week, and 3 sessions at least twice. Therefore,
individuals with S = 3 could be thought of as those who would be highly compliant with either
intervention during the pre-quit week phase of the trial.

7.2

Model specification

Compliance model. We considered numerous predictors of compliance at the model selection stage, including general characteristics of the subject (marital status, employment status,
race/ethnicity, age, income), measures of nicotine dependence (fagerstrom, number of cigarettes
smoked per day, age started smoking), previous quit attempts (number of quit attempts, ever quit
for 24 hours), need for and concern about weight loss (body mass index, percent fat, frequency of

18
Hosted by The Berkeley Electronic Press

dieting, weight fluctuation in a typical week). We selected a compliance model for each arm based
on parsimony, predictive accuracy and model fit, using the usual model selection techniques for
logistic regression models. For compliance with the contact condition, we decided on the following
model for ψ0(x),
logit −1 (λ00 + λ01 age + λ02 employ + λ03 married + λ05employ ∗ married + λ06ed12 + λ06ed15),
where age is years of age of the subject at baseline, employ is an indicator variable for employment
at baseline and married is an indicator variable that the subject is married, ed12 is the indicator
that the subject has at least 12 years of education, and ed15 is the indicator that the subject
had at least 15 years of education (i.e., some college). This model appeared to fit the data well
(Hosmer-Lemeshow goodness-of-fit statistic = 5.57 on 8 degrees of freedom; p = 0.69). For the
exercise condition, we chose the model
ψ1(x) = logit −1 (λ10 + λ11ed12 + λ12 ed15).
Covariates other than education level did not seemed to have an effect on the exercise compliance
probability.
Gibbs sampler. We specified uniform(0,1) priors for the πz (s) parameters, z = 0, 1, s =
0, · · · , 3. Proper, but relatively flat normal priors were assumed for the λ’s, with mean 0 and variance 1000. At each fixed value of φ, we generated 60,000 draws of the parameters using WinBUGS.
The first 10,000 draws were discarded. Convergence appeared to be reached by about the 1,000th
draw, based on trace plots and the Gelman-Rubin statistic.

7.3

Results

The value of φ affects the estimated number of subjects in each stratum (i.e., the size of each
compliance-type subpopulation). In Figure 2 we display estimates of the proportion of subjects
in each principal stratum at various values of φ. These estimates were calculated by generating
a value of S from the posterior distribution for each subject at each Gibbs draw, calculating the
proportion for each value of S, and then averaging those over all 50,000 draws. When φ was near
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0, there were a non-trivial number of subjects who would comply in one arm but not the other
(strata 1 and 2). When φ was near 1, nearly everyone that would comply in one arm would also
comply in the other. Therefore, the estimated proportion of subjects in strata 0 and 3 increased as
φ increased.
In Table 3 we present the 2.5, 50 and 97.5 percentiles of the posterior distribution of λ0 and λ1,
under the assumption of conditional independence (φ = 0); the results were similar at other values
of φ. For the contact compliance model, older subjects and those with more education appeared
to be more likely to comply. In addition, subjects who were married and unemployed were more
likely to comply than subjects who were married and employed, or who were not married. Based on
results from the exercise compliance model, subjects with 16 or more years of education appeared
more likely to comply than were subjects who had fewer years of education.
The 2.5, 50 and 97.5 percentiles of the posterior distribution of the πz (s) parameters are given
in Table 4. Among subjects that would be highly compliant with either intervention, we estimated
that the abstinence rate in the exercise arm was about 0.33, compared to about 0.16 for the contact
condition arm. The width of the corresponding credible intervals depends on the value of φ; the
intervals were the narrowest when φ was near 1, due to the fact that membership in stratum S = 3
would be largest when φ = 1 (see Figure 2). Overall quit rates appeared to vary from about 4%
(for those in stratum S = 0) to about 34% (for those in S = 2 or 3 who were randomized to receive
exercise).
Causal effect of exercise among compliers. Primary interest is in π1 (3) − π0 (3), the
difference in cessation rates between exercise and contact groups for the subgroup that would
comply with either intervention (S = 3). The posterior median, along with 95% credible interval
for this causal risk difference is displayed in Figure 3 (b), at various values of φ. For all values
of φ the posterior median is positive, indicating an estimated higher probability of cessation if
randomized to the exercise condition, among highly compliant subjects. For values of φ near 0, the
95% interval is very wide, indicating that we do not have much information about the intervention
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effect. A value of φ between 0.5 and 1 might be more plausible, however, as the two interventions
are similar in terms of what is expected from participants (both require attending a class 3 days
per week). For large values of φ, the interval becomes much more narrow, reflecting the fact that
class membership in group 3 increases (see Figure 2). The interval overlaps the null value of 0,
even when φ = 1, but most of the values in the interval are greater than 0. The posterior median
is 0.16 with 95% interval (−0.04, 0.36) at φ = 1.
Another way to compare treatments is to estimate the probability that cessation is higher if
randomized to exercise, among highly compliant subjects (S = 3). We recorded I{π1(s) > π0 (s)}
for each draw from the posterior. Here we focus on the s = 3 case. The average of these indicators
over the 50,000 samples is an estimate of the probability of a benefit of exercise over wellness among
compliers (S = 3). The results are presented in Figure 4 at various values of φ. As φ increases
towards 1, the benefit of exercise is more pronounced in the S = 3 stratum. If φ was near 0, the
evidence is weaker, but the probability of a benefit from exercise was still about 0.78.
Causal contrasts for other subpopulations. The model can be used to infer other contrasts
of potential interest, such as the effect of exercise among subjects that would comply with exercise,
but not wellness. For the CTQ study, this population is of interest because anecdotally, many
participants were attracted to the trial because of the exercise component. Figure 3 (a) displays
posterior quantiles of π1 (2) − π0(2) as a function of φ. As shown in Figure 1, when φ was near 0,
group membership in S = 2 was at its largest. Therefore, as φ increased, the credible intervals for
the ITT effect in arm S = 2 became wider. The majority of the posterior draws of the causal risk
difference were greater than 0, suggesting a benefit of exercise for this subpopulation. However, the
95% credible intervals always included 0, indicating that we cannot rule out no exercise benefit.
From Figure 4 we see that as φ decreased towards 0, it became highly likely that exercise was
beneficial in S = 2 stratum. If φ is near 1, the evidence was weaker, but the probability of a benefit
from exercise was still above 0.8.
We can also estimate the effect of being randomized to the exercise arm for strata the are
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unions of the basic principal stratification. For example, investigators might be interested in the
subpopulation that would comply with exercise if offered, regardless of whether or not they would
comply with the contact intervention (i.e., S = 2 or 3). In Figure 3 (c), we display the posterior
median and 95% credible interval for the intention-to-treat effect in the S = 2 or 3 subpopulation,
at various values of φ. The interval did not overlap with 0 at any value of φ, indicating a benefit of
exercise for this subpopulation. Also, notice that the interval was much less sensitive to values of φ
than were the effects for the population of compliers S = 3 or exercise-only compliers S = 2. The
reason that the width of the 95% interval for π1(3) − π0 (3) changed dramatically as a function of
φ, was that the estimated size of the population of S = 3 strictly increased as φ increased (Figure
2). However, if one were to estimate the proportion of subjects in S = 2 or 3 from Figure 2, we
would find that the number was nearly constant as a function of φ. As φ increased, there was a
shift from S = 2 to S = 3, but the combined population remained about the same. Because S = 2
or 3 included everyone that would comply with exercise, the information about that class comes
from the marginal distribution of A1 .
ITT effect for entire population. The traditional intention-to-treat analysis can be thought
of as the causal effect of Z on the entire population (i.e., those in strata S = 0, 1, 2 or 3). The sensitivity parameter φ has no impact here, as varying φ does not shift the population S ∈ {0, 1, 2, 3}.
The posterior median and 95% credible interval for the E(Y1 − Y0 ) was 0.085 (0.002, 0.170), suggesting a benefit of being randomized to the exercise group instead of the wellness group.
Characteristics of subjects in each stratum. The model proposed here can also be used
to characterize the covariate distribution of individuals in each principal stratum; i.e. [X | S],
as opposed to [S | X], which is summarized in Table 3. To illustrate, we estimated the average
value of each covariate in each stratum when φ = 0.5. We calculated the posterior probability that
S = s for every subject, at each value s = 0, · · · , 3 and then obtained the sample mean of each
covariate in stratum s by weighting by the posterior probability that S = s. The results are shown
in Table 5. Based on the results in the table, it appears that subjects that would comply with

22
Hosted by The Berkeley Electronic Press

the exercise condition but not the wellness condition (S = 2) were younger, more likely to have
more than 15 years of education, were more likely to be employed and less likely to be married,
than were subjects that would comply with the wellness condition, but not exercise (S = 1). The
stratum consisting of subjects that would comply with either intervention (S = 3) had the highest
percentage of subjects with more than 15 years of education.

7.4

The impact of covariates

We also explored the impact modeling compliance as a function of covariates by fitting a model with
no covariates in compliance models (1) and (2). As described previously, without covariates the
strata probabilities and causal effects are not point identified in this setting (2 active treatments).
There are bounds, however, on these parameters. Figure 5 includes plots of the estimated posterior
densities of π0 (3), π1 (3) and π1 (3) − π0 (3) in the models with and without covariates, for φ equal
to 0 and 1. When φ = 0, the posterior distributions from the model without covariates had flat
sections at the maximum height of the density. This reflected the fact that the data do not contain
enough information to identify a maximum point. Instead, there were a range of values that could
be viewed as ‘most likely.’ The plots from the model with covariates showed distributions that were
more narrow and had clear maximums. For φ equal to 1, as expected, the impact of covariates was
less pronounced because at φ = 1, a subject who complied with one intervention would also have
complied with the other. Observed compliance is essentially all that is needed to identify the strata
in that case. But since φ was unknown, Figure 5 demonstrates how conditioning on covariates in
the compliance models can reduce the range of likely values of the parameters of interest, over the
range of plausible values of φ.

8

Discussion

Experimental studies with two active treatments are fairly common, especially in behavioral intervention studies. When there is non-compliance in each arm, statistical comparisons between the
two interventions is challenging because the population of subjects that would comply with one
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intervention might differ from the population that would comply with the other. We have proposed
a model that utilizes compliance-predictive covariates to identify principal effects (causal contrasts
in subpopulations defined by compliance behavior) up to a sensitivity parameter. Identification
of the principal strata probabilities relies on the specification of two marginal compliance models, conditional on covariates, and an association model that ensures the joint probability remains
within the bounds of the parameter space. At each value of the association parameter, we are able
to make inference about the principal effects. As demonstrated in the simulation study and in the
data analysis, the inclusion of covariates in the compliance models effectively improves the precision
of the estimates of the causal effects. In the smoking cessation analysis, we found that subjects who
would comply with the exercise regimen would also tend to benefit from it. The evidence suggested
that the exercise regimen would yield better results than the wellness therapy, among subjects that
would comply with either intervention, although the results were not conclusive.
A philosophically satisfactory aspect of the principal stratification approach is that causal effects
are always defined in terms of comparisons between counterfactual outcomes indexed by a variable
over which the investigator has control. Using terminology from Pearl (2000), we can take an action
“assign the subject to treatment A,” but for some subjects, we cannot take the action “assign the
subject to treatment A and have them comply with treatment A.” Therefore, causal comparisons
between active treatments for the entire population are not as well defined as causal comparisons
between assigned treatments among meaningful subpopulations.
Our findings suggest that researchers who are planning trials with two active treatments would
benefit from collecting compliance information from both arms, as well as baseline covariate information that they expect will be predictive of compliance. By collecting this additional information,
the methods described in this paper can be used to identify causal effects among subpopulations
defined by their compliance pattern. This should provide investigators with a far greater understanding of the effects of the two treatments, beyond what could be learned from the usual intention
to treat approach.
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Areas of future research include developing methods for longitudinal data, where compliance
and/or the response are measured repeatedly over time. In the CTQ trial, compliance and quit
status were measured weekly. Because our focus was on continual abstinence, we needed to define
compliance during the pre-quit day period (in order for the exposure to preceed the outcome).
However, if one were interested in weekly quit status as an outcome, the methods proposed here
could be extended to include weekly compliance data in order to estimate the principal effects at
each visit. Similarly, if compliance status was observed at multiple time points, but the outcome
was just observed at the end of the study (e.g., week 12 quit status), the ideas proposed here could
be extended to investigate the effect of different types of compliance patterns on the outcome.
For example, for longitudinal trials with one active treatment, Lin, Ten Have and Elliott (2006)
describe a model based on latent compliance classes that characterize different compliance patterns
over time; a similar approach might be reasonable here.
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Table 2: Results from simulation study for inference about π1 (3) − π0(3) (true value is 0.2). Results
are reported for true values of φ equal to 0.1 and 0.9, and for the two compliance models (c = 1
and c = 2). 1000 simulated data sets for each scenario were used.
Model

median

1
2
3

0.19
0.17
0.16

1
2
3

0.19
0.16
0.15

1
2
3

0.20
0.21
0.20

1
2
3

0.20
0.21
0.20

ESD width coverage
φ = 0.1, c = 1
0.10
0.32
0.90
0.11
0.89
1.00
0.15
0.75
0.98
φ = 0.1, c = 2
0.09
0.32
0.91
0.11
0.92
1.00
0.14
0.63
0.96
φ = 0.9, c = 1
0.08
0.27
0.90
0.09
0.37
0.96
0.09
0.35
0.95
φ = 0.9, c = 2
0.08
0.28
0.90
0.09
0.43
0.97
0.09
0.34
0.93

Table 3: Estimates of the 2.5, 50 and 97.5 percentiles of the posterior distribution of the compliance
model parameters when φ = 0.
Parameter
2.5
50
contact compliance model
Intercept
-4.36 -2.33
age
0.02 0.06
employed
-1.15 0.01
married
-0.02 1.31
married*employed -3.15 -1.56
education ≤ 12 yrs -0.67 0.19
education ≤ 15 yrs -1.74 -0.81
exercise compliance model
Intercept
-0.21 -0.49
education ≤ 12 yrs -1.22 -0.41
education ≤ 15 yrs -1.82 -0.89

97.5
-0.50
0.10
1.21
2.73
-0.02
1.04
0.07
1.21
0.39
0.01
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Table 4: Posterior median and 95% credible interval for the cessation probability parameters at φ
equal 0, 0.5 and 1.
Parameter
π0(0)
π0(1)
π0(2)
π0(3)
π1(0)
π1(1)
π1(2)
π1(3)

φ=0
0.04 (0.002, 0.12)
0.24 (0.03, 0.48)
0.07 (0.004, 0.23)
0.16 (0.01, 0.52)
0.04 (0.002, 0.17)
0.14 (0.02, 0.36)
0.33 (0.06, 0.63)
0.34 (0.04, 0.74)

φ = 0.5
0.04 (0.002, 0.10)
0.33 (0.04, 0.70)
0.09 (0.004, 0.33)
0.13 (0.01, 0.37)
0.04 (0.002, 0.15)
0.19 (0.02, 0.53)
0.35 (0.03, 0.79)
0.33 (0.08, 0.59)

φ=1
0.05 (0.02, 0.10)
0.34 (0.04, 0.83)
0.09 (0.004, 0.55)
0.18 (0.07, 0.32)
0.04 (0.002, 0.13)
0.26 (0.03, 0.79)
0.36 (0.03, 0.88)
0.33 (0.18, 0.50)

Table 5: Estimated average value of covariates in each principal stratum.
Covariate
Age
Education ≤ 12 yrs
Education 13 − 15 yrs
Education > 15 yrs
Employed
Married

S=0
38.5
0.42
0.42
0.16
0.82
0.50

S=1
44.0
0.50
0.30
0.20
0.57
0.63

S =2
37.8
0.26
0.41
0.33
0.83
0.44

S=3
42.2
0.30
0.30
0.40
0.72
0.48
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0.5

Figure 2: Estimated proportion of population in each principal stratum at each value of φ.
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Figure 3: Plot of 2.5, 50 and 97.5 percentiles of posterior distribution of the risk difference for
stratum 2, π1(2) − π0(2), in figure (a), for stratum 3, π1(3) − π0(3), in figure (b), and the combined
stratum 2 and 3, π1(S ∈ {2, 3}) − π0(S ∈ {2, 3}),in figure (c), at different values of φ.
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1.0

Figure 4: Plot of the posterior mean of I(π1(s) > π0 (s)), for strata s = 2, 3, at different values of
φ. This all can be viewed as an estimate of the probability that cessation is more likely if assigned
exercise in each stratum.
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Figure 5: Plot of posterior distribution of π0 (3), π1 (3) and π1 (3) − π0 (3) for the models with and
without covariates, and at φ = 0 and φ = 1
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